On September 25, 2024, Pfizer Inc. (NYSE: PFE) announced the voluntary global withdrawal of OXBRYTA® (voxelotor), its treatment for sickle cell disease (SCD), due to safety concerns. This decision follows
All posts tagged in treating hemolytic anemia
1Article
